$102.98
0.060.06%
Last update: Nov 10, 7:49 PM
Halozyme Therapeutics Inc
HALONASDAQ
The average analyst price target for Halozyme Therapeutics is $92.76, 8.4% below the current price. Of 11 analysts, 7 rate it Buy and 4 Hold. Targets range from $47 to $149. The latest change came on Nov 6, 2026, when Leerink Partners downgraded Halozyme Therapeutics from Outperform to Market Perform and moved its price target from $110 to $117.
Price Target Range — 13 Quarters
Analyst Consensus — 11 Analysts
Rating Trend — Last 9 Months
